Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge [Yahoo! Finance]
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? [Yahoo! Finance]
ACADIA Pharmaceuticals (ACAD) had its price target raised by JPMorgan Chase & Co. from $31.00 to $34.00. They now have an "overweight" rating on the stock.
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors [Yahoo! Finance]
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors